EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Impact of CYP2C19 Genotype Variants on PCSK9 Inhibitor Efficacy in Lipid‐Lowering Among Patients With Symptomatic Intracranial Atherosclerotic Stenosis

Chao Zhao iD, Nuan Wang, Di Shi, Hao Zhou, Dan Chen, Guofang Chen

Lipids · 2025

DOI: 10.1002/lipd.70018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lipids, 2025. Verfasst von Chao Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Suzhou Medical College of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: PCSK9 Inhibitors, Cytochrome P-450 CYP2C19, Intracranial Arterial Diseases, Atherosclerosis. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Development fund of Affiliated Hospital of Xuzhou Medical UniversityDevelopment fund of Affiliated Hospital of Xuzhou Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ischemic stroke is frequently associated with symptomatic intracranial atherosclerotic stenosis (sICAS), is a leading cause of global disability and mortality. Current guidelines recommend dual antiplatelet and intensive statin therapies. Proprotein convertase subtilisin 9/kexin type 9 (PCSK9) inhibitors have emerged as a potent lipid‐lowering therapy, potentially influenced by genetic variations, particularly in the CYP2C19 gene. This study at Xuzhou Central Hospital from January 2021 to December 2023 included 151 patients divided into a statin group ( n = 73) and a PCSK9 inhibitor (PCSK9i) group ( n = 78). It evaluated lipid profiles, inflammatory markers, neurological function, and clinical outcomes over a 180‐day follow‐up period, with additional analysis stratified by CYP2C19 genotype. The PCSK9i group demonstrated significant improvements in lipid parameters compared to the statin group, including greater reductions in low‐density lipoprotein cholesterol (LDL‐C) ( p = 0.008), total cholesterol (TC) ( p < 0.001), and triacylglycerols (TAG) ( p = 0.041), along with apolipoprotein A1 (ApoA1) and apolipoprotein B (ApoB) (both p < 0.001). Inflammatory markers, particularly interleukin‐6 (IL‐6), significantly reduced in the PCSK9i group ( p < 0.001). In the PCSK9i group, CYP2C19 rapid metabolizers achieved greater reductions in LDL‐C ( p = 0.021), ApoB ( p = 0.003), and IL‐6 levels ( p = 0.041) compared to slow metabolizers. Post‐treatment modified Rankin Scale (mRS) scores were significantly lower in rapid metabolizers compared to slow metabolizers ( p = 0.018), though clinical events occurred infrequently in both subgroups. This study demonstrates that PCSK9 inhibitor therapy combined with statins provides enhanced lipid‐lowering and anti‐inflammatory effects compared to statin monotherapy in sICAS patients. While the CYP2C19 genotype may influence specific treatment responses, particularly lipid parameters, its impact on clinical outcomes requires further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PCSK9 InhibitorsCytochrome P-450 CYP2C19Intracranial Arterial DiseasesAtherosclerosisLipid MetabolismRetrospective StudiesConstriction, PathologicPharmacogenomic VariantsHumansMaleFemaleMiddle AgedAgedTreatment OutcomeHydroxymethylglutaryl-CoA Reductase Inhibitors

Stichwörter der Autor:innen

CYP2C19LDL‐CPCSK9 inhibitorintracranial atherosclerotic stenosisstatins

Substanzen

PCSK9 InhibitorsCYP2C19 protein, humanCytochrome P-450 CYP2C19Hydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Department of Neurology, Suzhou Medical College of Soochow University, Suzhou, China.
  • Department of Neurology, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou, China.
  • Xuzhou First People's Hospital, Xuzhou, China.
  • Department of Neurology, Xuzhou Central Hospital, Xuzhou, China.

ORCID-Profile: Chao Zhao

Förderung

  • Development fund of Affiliated Hospital of Xuzhou Medical UniversityDevelopment fund of Affiliated Hospital of Xuzhou Medical University

Zitieren

APA

Zhao, C., Wang, N., Shi, D., Zhou, H., Chen, D., & Chen, G. (2025). Impact of CYP2C19 Genotype Variants on PCSK9 Inhibitor Efficacy in Lipid‐Lowering Among Patients With Symptomatic Intracranial Atherosclerotic Stenosis. Lipids. https://doi.org/10.1002/lipd.70018

Vancouver

Zhao C, Wang N, Shi D, Zhou H, Chen D, Chen G. Impact of CYP2C19 Genotype Variants on PCSK9 Inhibitor Efficacy in Lipid‐Lowering Among Patients With Symptomatic Intracranial Atherosclerotic Stenosis. Lipids. 2025. doi:10.1002/lipd.70018

BibTeX
@article{Zhao2025,
  author = {Zhao, Chao and Wang, Nuan and Shi, Di and Zhou, Hao and Chen, Dan and Chen, Guofang},
  title = {Impact of CYP2C19 Genotype Variants on PCSK9 Inhibitor Efficacy in Lipid‐Lowering Among Patients With Symptomatic Intracranial Atherosclerotic Stenosis},
  journal = {Lipids},
  year = {2025},
  doi = {10.1002/lipd.70018}
}
Kostenlos starten →